ca_fisherman, dugs can get approved after a successful phase II, especially when there is an unmet need. Azedra is an ultra-orphan drug so it may just fit the bill if the data is good enough.
I see where I was confused about what you were saying. Yes, PGNX needs to finish the phase II trial first.
Chiraag, I don't know what you are talking about. We were all discussing the phase 2 trial. Azedra hasn't been tested in a phase 3 trial so the FDA obviously has made no comments on that.
Why are you lying? Relistor sales were $44 million last year and that is before the large chronic pain indication was approved by the FDA.
Barc, it is fine if you don't know and ask questions but stop lying. The market is full of idiots who are swayed by incomplete or misleading reports. PGNX stock price will soon rebound when reality sets in. SLXP reported that Relistor prescription increased 37% in Q4 over Q3. SLXP had issues of wholesaler stockpiling but stated Rvenues would have been $12 million in Q4 alone absent those issues. Relistor is now approved for chronic pain and sales will ramp up even more.
Ca_fisherman, that makes sense. I guess I was a little annoyed by the large unwarranted price drop. In any event, where the stock price ends today or this week is irrelevant to me.
European approval will be big for PGNX as they get 50%-60% of the revenues as opposed to 15%-20% for US sales of Relistor.
taraddsmoot, You sound like the Ultimate idiot for believing in Ultimate Stock Alerts.
If you learned some basic math you wouldn't make such a comment. It is no dream. V-Pak will have 25% of the Hep-C market. I am pleased that are many people like you in the investment community as it makes it easy to make money.
I appreciate the input but what happens in one small Medical grou isn't very informative. Don't forget about the Medicaid market.
Right, 20 doctors from rich Orange County are indicative of the entire Hep-C market across the country, including Medicaid. Thanks for the amusing anecdote.
Using virus as anti-cancer therapies has been going on for at least a decade. There are a lot of issues to be worked out. The idea that any viral based anti-cancer therapy will be approved in 2016 is absurd. Next time try to avoid using TV as a source for your investment information.
I didn't suggest or even remotely imply that you were bashing SNTA. I made a very clear point, that going by what HBO or any TV show says is absurd. It is also absurd to think you can get some important insight from a sound-bite given by any researcher on a TV show. Important information comes from controlled trill and peer reviewed studies. Don't take that as a personal affront.
I had no idea that PGNX had a partner in 1404. I assume that the partner was in place before PGNX acquired 1404. That is good news but it would be nice if PGNX management informed shareholders about it and provided us the terms of the partnership, especially milestone payments.